Novel Use of Anti-BLyS Antibodies
AssigneesGlaxoSmithKline Intellectual Property Management Limited, GlaxoSmithKline Intellectual Property Limited
InventorsElaine IRVING, Mary MORSE, Svetlana NIHTYANOVA
Life of this patent
Estimating the term…
Abstract
The present disclosure provides anti-BlyS antibodies for use in the treatment of connective tissue disease, in particular, connective tissue disease-associated interstitial lung disease, including systemic sclerosis, in particular, systemic sclerosis associated interstitial lung disease, for example, diffuse cutaneous systemic sclerosis-associated interstitial lung disease. Also provided is a method for the treatment of connective tissue disease-associated interstitial lung disease, including systemic sclerosis associated-interstitial lung disease comprising administering to a subject in need thereof a therapeutically effective amount of an anti-BlyS antibody.
Claims22
1-40. (canceled)
A method for treatment of connective tissue disease-associated interstitial lung disease using an anti-BlyS antibody in a human subject in need thereof, wherein the connective tissue disease-associated interstitial lung disease comprises systemic sclerosis-associated interstitial lung disease, rheumatoid arthritis-associated interstitial lung disease, Sjögren's syndrome-associated interstitial lung disease, an idiopathic inflammatory myopathy-associated interstitial lung disease, and/or mixed connective tissue disease-associated interstitial lung disease, and wherein the connective tissue disease-associated interstitial lung disease does not comprise systemic lupus erythematosus-associated interstitial lung disease.
Dependencies are inferred from the claim text.